Diabetes, Atherosclerosis, and Stenosis by AI.

"Duality of Interest. J.P.E., H.M., J.K.M., and A.D.C. have equity interest in Cleerly Inc. J.P.E., R.S.J., T.R.C., and J.K.M. are employees of Cleerly Inc. No other potential conflicts of interest relevant to this article were reported."

"Funding. A.D.C. is supported by a grant from theGW Heart and Vascular Institute."

"The study population comprised the derivation cohort of the CREDENCE trial (clinicaltrials.gov NCT02173275), which was a prospective, multicenter diagnostic derivation-validation controlled clinical trial recruiting stable patients from 2014 to 2017 with a locked database completed in 2018 () along with a detailed design manuscript (). Eligibility criteria included referral for nonemergent invasive coronary angiography (ICA) based on the American College of Cardiology/American Heart Association clinical practice guidelines for stable ischemic heart disease. All index tests were interpreted in blinded fashion by core laboratories. The Institutional Review Board of each enrolling site approved the study protocol, and all patients provided written informed consent. Patient demographics, cardiovascular risk factors, laboratory values, and medications were prospectively collected and recorded at the time of baseline and follow-up CCTAs."